The Premier Consulting Blog

JUNE 18, 2023

This has opened new opportunities in pharmaceutical drug development, such as the ability to evaluate large complex databases and to integrate information in useful ways. One exciting application of these technologies is the use of in silico trials in the development of novel therapies for rare diseases.

Drug Development 52

Drug Development Disease Clinical Trials Drugs 52

Drug Target Review

DECEMBER 6, 2024

For more: [link] ; [link] ; [link] ; [link] Nina Truter Nina Truter is a translational scientist with a deep focus on understanding mechanisms of action in drug development and leveraging disparate datasets in biotech. In 2003, he was selected by EE Times as one of the top 13 most influential people in the semiconductor industry.

RNA 52

RNA Drugs Research Science 52

Drug Target Review

JULY 12, 2023

The clinical-stage oncology company develops medicines for broad populations of cancer patients and aims to achieve universal-RAS activity through deep cyclic inhibition of the mitogen-activated protein kinase (MAPK) pathway, selectively impacting cancer cells while sparing healthy cells.

Biochemical Assays 98

Biochemical Assays Treatment Bioinformatics Disease 98

Elrig

APRIL 29, 2024

With a background in Bioinformatics and Computational Biology, she has a keen interest in using technology to solve problems in healthcare and medicine. Harini joined Serna Bio in early 2021 and has been an integral part of the multidisciplinary teamworking on target ID platform development to drug discovery.

Bioinformatics 59

Bioinformatics Drugs Molecular Biology Cell Based Assays 59

Drug Target Review

MAY 27, 2024

We feel that target discovery is the gatekeeper to successful drug development and can maximize our probability of success through diversified and thoughtful partnerships with biopharma. We are excited about our recently announced partnership with Merck KGaA, Darmstadt, Germany to discover and validate novel ADC targets.

Clinical Trials 59

Clinical Trials Science Molecular Biology Bioinformatics 59

Drug Target Review

APRIL 11, 2025

Drug development is hampered by high costs, long timelines and a low probability of success and complex therapies exacerbate these challenges. Even excluding repositioned drugs, which could benefit from pre-existing toxicology and clinical data, a significant increase in PoS is still observed. This is an AI-generated image.

Clinical Development 52

Clinical Development Drugs Pharmaceuticals Clinical Trials 52

Vial

DECEMBER 5, 2023

It has become a fundamental tool for researchers to explore the complexities of genetic information and conduct genetic-informed drug development. Sponsors have used NGS to screen patients for clinical trial eligibility and patient stratification , expanded CDx development, and comprehensive genomic profiling (CGP). Satam et al.

Clinical Trials 52

Clinical Trials Trials RNA Bioinformatics 52